← All trials
NCT06872892
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2025
- Primary completion
- Sep 14, 2028
- Completion date
- Oct 12, 2028
- First posted
- Mar 12, 2025
- Last posted
- Mar 12, 2025
- Enrollment
- 1680
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.